EyePoint (EYPT) Other Non Operating Income (2010 - 2026)
EyePoint (EYPT) posted Other Non Operating Income of $2.3 million for Q1 2026, down 19.78% sequentially from $2.9 million in Q4 2025, and down 35.64% YoY from $3.6 million in Q1 2025.
Analysis
EyePoint (EYPT) Other Non Operating Income (2010 - 2026) Analysis & Trends
EyePoint has reported Other Non Operating Income for 17 years, with the latest figure at $2.3 million in Q1 2026.
- Quarterly Other Non Operating Income fell 35.64% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.5 million (down 28.86% YoY) and the FY2025 annual result came in at $11.8 million, down 22.12% from the prior year.
- Other Non Operating Income declined to $2.3 million in Q1 2026 per EYPT's latest filing, from $2.9 million in the prior quarter.
- Over five years, Other Non Operating Income peaked at $4.0 million in Q1 2024 and troughed at -$2.6 million in Q4 2022.
- A 5-year average of $1.9 million and a median of $2.3 million in 2023 frame the typical range for Other Non Operating Income.
- The widest YoY moves for Other Non Operating Income: up 10566.67% in 2022, down 156000.0% in 2022.
- Over 5 years, Other Non Operating Income stood at -$2.6 million in 2022, then jumped by 189.03% to $2.3 million in 2023, then soared by 68.69% to $3.9 million in 2024, then dropped by 25.91% to $2.9 million in 2025, then fell by 19.78% to $2.3 million in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $2.3 million, $2.9 million, and $2.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.91 Mn |
| Mar 31, 2026 | 2.34 Mn |
| Dec 31, 2025 | 2.96 Mn |
| Sep 30, 2025 | 2.29 Mn |
| Jun 30, 2025 | 2.89 Mn |
| Mar 31, 2025 | 3.64 Mn |
| Dec 31, 2024 | 3.94 Mn |
| Sep 30, 2024 | 3.39 Mn |
| Jun 30, 2024 | 3.72 Mn |
| Mar 31, 2024 | 4.04 Mn |
| Dec 31, 2023 | 2.34 Mn |
| Sep 30, 2023 | 1.79 Mn |
| Jun 30, 2023 | 1.62 Mn |
| Mar 31, 2023 | 1.20 Mn |
| Dec 31, 2022 | 3.69 Mn |
| Sep 30, 2022 | 640,000.00 |
| Jun 30, 2022 | 362,000.00 |
| Mar 31, 2022 | -1.56 Mn |
| Sep 30, 2021 | 6,000.00 |
| Jun 30, 2021 | 2.07 Mn |